Sangamo Therapeutics Inc (SGMO) reports significant progress in clinical trials and funding, despite facing regulatory uncertainties and cash management hurdles.
Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across ...
Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across al ...
Sangamo Therapeutics, a company at the forefront of gene therapy and genomic medicine development, has made significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results